Be among trailblazing marketing pros at Brandweek this September 23–26 in Phoenix, Arizona. Experience incredible networking, insightful sessions and a boost of inspiration at ADWEEK’s ultimate brand event. Register by May 13 to save 35%.
Competitive pressure, rather than a search for greater efficiency, may be behind Eli Lilly & Co.’s decision last week to review its media planning and buying business. And that may mean the company will spend considerably more than last year’s $70 million, sources said.
The Indianapolis-based pharmaceutical giant is preparing to launch a new drug next year to compete with Pfizer’s Viagra, while its antidepressant Prozac faces new competition. In its third-quarter earnings report released last week, Lilly disclosed that its earnings fell 27 percent to $570 million, compared with $779 million a year ago.
This
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in